Status:
COMPLETED
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
Lead Sponsor:
Bayer
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total popula...
Eligibility Criteria
Inclusion
- Male or female patients ≥ 18 years of age.
- Patients who suffer from mCRC and who started treatment with Stivarga between the 1st of July 2015 and 31 July 2017.
- Patients who already received alternative treatment options before Stivarga for the treatment of mCRC or who were not eligible for other treatment options.
- Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 at start of Stivarga treatment.
- Sufficient kidney, liver and bone marrow function start of Stivarga treatment.
- Life expectancy ≥ 3 months at start of Stivarga treatment
Exclusion
- \- Patients participating in an investigational program/clinical trial with interventions outside of routine clinical practice during the observational period.
Key Trial Info
Start Date :
January 31 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03386825
Start Date
January 31 2018
End Date
May 1 2018
Last Update
May 15 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Belgium
Multiple Locations, Belgium